Glycogen storage disease

A glycogen storage disease (GSD, also glycogenosis and dextrinosis) is a metabolic disorder caused by enzyme deficiencies affecting either glycogen synthesis, glycogen breakdown or glycolysis (glucose breakdown), typically in muscles and/or liver cells.[1]

Glycogen storage disease
Other names	Glycogenosis, dextrinosis
Glycogen
Specialty	Endocrinology

GSD has two classes of cause: genetic and acquired. Genetic GSD is caused by any inborn error of metabolism (genetically defective enzymes) involved in these processes. In livestock, acquired GSD is caused by intoxication with the alkaloid castanospermine.[2]

Types

Type (Eponym)	Enzyme deficiency (Gene[3])	Incidence (births)	Hypo- glycemia?	Hepato- megaly?	Hyperlip- idemia?	Muscle symptoms	Development/ prognosis	Other symptoms
GSD 0	Glycogen synthase (GYS2)	?	Yes	No	No	Occasional muscle cramping	Growth failure in some cases
GSD I / GSD 1 (von Gierke's disease)	Glucose-6-phosphatase (G6PC / SLC37A4)	1 in 50,000 – 100,000[4][5] [6]	Yes	Yes	Yes	None	Growth failure	Lactic acidosis, hyperuricemia
GSD II / GSD 2 (Pompe disease )	Acid alpha-glucosidase (GAA)	1 in 13,000. [7]	No	Yes	No	Muscle weakness	Progressive proximal skeletal muscle weakness with varied timeline to threshold of functional limitation (early childhood to adulthood). Approximately 15% of the Pompe population is classified as infantile Pompe which is typically deadly within the first year if untreated.	Heart failure (infantile), respiratory difficulty (due to muscle weakness)
GSD III / GSD 3 (Cori's disease or Forbes' disease)	Glycogen debranching enzyme (AGL)	1 in 100,000	Yes	Yes	Yes	Myopathy
GSD IV / GSD 4 (Andersen disease)	Glycogen branching enzyme (GBE1)	1 in 500,000[8]	No	Yes, also cirrhosis	No	Myopathy and dilated cardiomyopathy	Failure to thrive, death at age ~5 years
GSD V / GSD 5 (McArdle disease)	Muscle glycogen phosphorylase (PYGM)	1 in 100,000 – 500,000[9][8]	No	No	No	Exercise-induced cramps, Rhabdomyolysis		Renal failure by myoglobinuria, second wind phenomenon
GSD VI / GSD 6 (Hers' disease)	Liver glycogen phosphorylase (PYGL) Muscle phosphoglycerate mutase (PGAM2)	1 in 65,000 – 85,000[10]	Yes	Yes	Yes [11]	None	initially benign, developmental delay follows.
GSD VII / GSD 7 (Tarui's disease)	Muscle phosphofructokinase (PFKM)	1 in 1,000,000[12]	No	No	No	Exercise-induced muscle cramps and weakness	developmental delay	In some haemolytic anaemia
GSD IX / GSD 9	Phosphorylase kinase (PHKA2 / PHKB / PHKG2 / PHKA1)	?	Yes	Yes	Yes	None	Delayed motor development, Developmental delay
GSD X / GSD 10	Phosphoglycerate mutase (PGAM2)	?	?	?	?	Exercise-induced muscle cramps and weakness		Myoglobinuria[13]
GSD XI / GSD 11	Muscle lactate dehydrogenase (LDHA)	?	?	?	?
Fanconi-Bickel syndrome formerly GSD XI / GSD 11, no longer considered a GSD	Glucose transporter (GLUT2)	?	Yes	Yes	No	None
GSD XII / GSD 12 (Aldolase A deficiency)	Aldolase A (ALDOA)	?	No	In some	No	Exercise intolerance, cramps. In some Rhabdomyolysis.		Hemolytic anemia and other symptoms
GSD XIII / GSD 13	β-enolase (ENO3)	?	No	?	No	Exercise intolerance, cramps	Increasing intensity of myalgias over decades[14]	Serum CK: Episodic elevations; Reduced with rest[14]
GSD XV / GSD 15	Glycogenin-1 (GYG1)	Rare[15]	No	No	No	Muscle atropy	Slowly progressive weakness over decades	None

Remarks:

• Some GSDs have different forms, e.g. infantile, juvenile, adult (late-onset).
• Some GSDs have different subtypes, e.g. GSD1a / GSD1b, GSD9A1 / GSD9A2 / GSD9B / GSD9C / GSD9D.[3]
• GSD type 0: Although glycogen synthase deficiency does not result in storage of extra glycogen in the liver, it is often classified with the GSDs as type 0 because it is another defect of glycogen storage and can cause similar problems.
• GSD type VIII (GSD 8): In the past it was considered a distinct condition,[16] however it is now classified with GSD type VI[17] or GSD IXa1;[18] it has been described as X-linked recessive inherited.[19]
• GSD type XI (GSD 11): Fanconi-Bickel syndrome, hepatorenal glycogenosis with renal Fanconi syndrome, no longer considered a glycogen storage disease.[3]
• GSD type XIV (GSD 14): Now classed as Congenital disorder of glycosylation type 1 (CDG1T), affects the phosphoglucomutase enzyme (gene PGM1).[3]
• Lafora disease is considered a complex neurodegenerative disease and also a glycogen metabolism disorder.[20]

Diagnosis

Micrograph of glycogen storage disease with histologic features consistent with Cori disease. Liver biopsy. H&E stain.

Treatment

Treatment is dependent on the type of glycogen storage disease. GSD I is typically treated with frequent small meals of carbohydrates and cornstarch, called modified cornstarch therapy, to prevent low blood sugar, while other treatments may include allopurinol and human granulocyte colony stimulating factor.[21]

Epidemiology

Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease.[22] In the United States, they are estimated to occur in 1 per 20,000–25,000 births.[4] Dutch incidence rate is estimated to be 1 per 40,000 births. While a Mexican incidence showed 6.78:1000 male newborns.[23][24]

References

1. Cantú-Reyna, C.; Santos-Guzmán, J.; Cruz-Camino, H.; Vazquez Cantu, D.L.; Góngora-Cortéz, J.J.; Gutiérrez-Castillo, A. (2019). "Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population". Journal of Neonatal-Perinatal Medicine: 1–5. doi:10.3233/NPM-1831. PMID 30741698.
2. Stegelmeier BL, Molyneux RJ, Elbein AD, James LF (May 1995). "The lesions of locoweed (Astragalus mollissimus), swainsonine, and castanospermine in rats". Veterinary Pathology. 32 (3): 289–98. doi:10.1177/030098589503200311. PMID 7604496.
3. Glycogen Metabolism themedicalbiochemistrypage.org
4. eMedicine Specialties > Glycogen-Storage Disease Type I Author: Karl S Roth. Updated: Aug 31, 2009
5. The Association for Glycogen Storage Disease > Type I Glycogen Storage Disease Type I GSD Archived 2010-08-03 at the Wayback Machine October 2006.
6. Cantú-Reyna, C.; Santos-Guzmán, J.; Cruz-Camino, H.; Vazquez Cantu, D.L.; Góngora-Cortéz, J.J.; Gutiérrez-Castillo, A. (4 February 2019). "Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population". Journal of Neonatal-Perinatal Medicine: 1–5. doi:10.3233/NPM-1831. PMID 30741698.
7. https://pediatrics.aappublications.org/content/140/Supplement_1/S4
8. Stuart, Grant; Ahmad, Nargis (2011). "Perioperative care of children with inherited metabolic disorders". Continuing Education in Anaesthesia Critical Care & Pain. 11 (2): 62–68. doi:10.1093/bjaceaccp/mkq055.
9. http://mcardlesdisease.org/
10. eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases > Glycogen-Storage Disease Type VI Author: Lynne Ierardi-Curto, MD, PhD. Updated: Aug 4, 2008
11. Goldman, Lee; Schafer, Andrew (2012). Goldman's Cecil medicine (24th ed.). Philadelphia: Elsevier/Saunders. p. 1356. ISBN 978-1-4377-1604-7.
12. "Rare Disease Database". Orpha.net. Retrieved 2015-09-20.
13. Reference, Genetics Home. "Phosphoglycerate mutase deficiency". Genetics Home Reference. Retrieved 2019-02-06.
14. "Glycogenoses".
15. Malfatti E, Nilsson J, Hedberg-Oldfors C, Hernandez-Lain A, Michel F, Dominguez-Gonzalez C, Viennet G, Akman HO, Kornblum C, Van den Bergh P, Romero NB, Engel AG, DiMauro S, Oldfors A (2014) A new muscle glycogen storage disease associated with glycogenin-1 deficiency. Ann Neurol 76(6):891-898
16. Ludwig M, Wolfson S, Rennert O (October 1972). "Glycogen storage disease, type 8". Arch. Dis. Child. 47 (255): 830–833. doi:10.1136/adc.47.255.830. PMC 1648209. PMID 4508182.
17. "Glycogen-Storage Disease Type VI : Article by Lynne Ierardi-Curto". eMedicine. 2019-02-02.
18. GLYCOGEN STORAGE DISEASE IXa1; GSD9A1 OMIM - Online Mendelian Inheritance in Man
19. "Definition: glycogen storage disease type VIII from Online Medical Dictionary".
20. Ortolano S, Vieitez I et al. Loss of cortical neurons underlies the neuropathology of Lafora disease. Mol Brain 2014;7:7 PMC 3917365
21. "Glycogen Storage Disease Type I - NORD (National Organization for Rare Disorders)". NORD (National Organization for Rare Disorders). Retrieved 23 March 2017.
22. Applegarth DA, Toone JR, Lowry RB (January 2000). "Incidence of inborn errors of metabolism in British Columbia, 1969–1996". Pediatrics. 105 (1): e10. doi:10.1542/peds.105.1.e10. PMID 10617747.
23. Cantú-Reyna, C.; Santos-Guzmán, J.; Cruz-Camino, H.; Vazquez Cantu, D.L.; Góngora-Cortéz, J.J.; Gutiérrez-Castillo, A. (4 February 2019). "Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population". Journal of Neonatal-Perinatal Medicine: 1–5. doi:10.3233/NPM-1831. PMID 30741698.
24. Cantú-Reyna, Consuelo; Zepeda, Luis Manuel; Montemayor, René; Benavides, Santiago; González, Héctor Javier; Vázquez-Cantú, Mercedes; Cruz-Camino, Héctor (27 September 2016). "Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital" (PDF). Journal of Inborn Errors of Metabolism and Screening. 4: 232640981666902. doi:10.1177/2326409816669027.

External links

Classification	D ICD-10: E74.0 ICD-9-CM: 271.0 MeSH: D006008